Liquidia (NASDAQ:LQDA) Price Target Raised to $87.00

Liquidia (NASDAQ:LQDA) had its price target lifted by BTIG Research from $70.00 to $87.00 in a report released on Tuesday morning, MarketBeat.com reports. BTIG Research currently has a buy rating on the stock.

Several other research analysts also recently commented on the company. Wells Fargo & Company lifted their target price on Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 14th. Needham & Company LLC dropped their price target on Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. Stephens set a $130.00 price target on Liquidia in a report on Friday, July 24th. Jefferies Financial Group raised Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. Finally, Piper Sandler set a $129.00 price objective on shares of Liquidia in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $74.38.

Liquidia Stock Up 5.3%

Liquidia stock opened at $58.12 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.02 and a quick ratio of 2.12. The company’s 50-day moving average is $49.19 and its 200-day moving average is $54.68. The firm has a market capitalization of $5.24 billion, a PE ratio of 24.98, a P/E/G ratio of 0.75 and a beta of 0.40. Liquidia has a fifty-two week low of $22.31 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Tuesday, November 10th. The company reported ($2.64) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($3.60). The firm had revenue of $225.30 million during the quarter, compared to analyst estimates of $214.18 million. Liquidia had a negative net margin of 15.15% and a positive return on equity of 264.65%. The company’s revenue for the quarter was up 314.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) earnings per share. Sell-side analysts anticipate that Liquidia will post 1.32 earnings per share for the current year.

Insider Transactions at Liquidia

In related news, Director Katherine Rielly-Gauvin sold 36,789 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $74.99, for a total value of $2,758,807.11. Following the transaction, the director directly owned 44,637 shares in the company, valued at approximately $3,347,328.63. This represents a 45.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Roger Jeffs sold 32,744 shares of the firm’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $932,549.12. Following the transaction, the chief executive officer directly owned 1,125,848 shares in the company, valued at approximately $32,064,151.04. This represents a 2.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 566,579 shares of company stock worth $25,746,120. 25.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in shares of Liquidia in the second quarter valued at approximately $29,694,000. Bank of America Corp DE lifted its position in shares of Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares during the period. Public Sector Pension Investment Board grew its holdings in shares of Liquidia by 90.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 458,708 shares of the company’s stock worth $13,881,000 after purchasing an additional 217,332 shares in the last quarter. Eversept Partners LP grew its holdings in shares of Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its position in shares of Liquidia by 124.5% in the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after purchasing an additional 113,609 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia News Roundup

Here’s some of the latest news about LQDA:

• Positive Sentiment: Liquidia reported $222.7 million in third-quarter YUTREPIA product sales, up 31% from the prior quarter. October shipments reached a monthly record, and the prescriber base grew to about 1,300. The company also said its settlement with United Therapeutics resolved pending litigation and allows YUTREPIA to remain available without disruption. Article: LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
• Positive Sentiment: Raymond James upgraded LQDA to Strong Buy and raised its target to $77 from $53, citing the YUTREPIA launch. Needham also raised its target to $66 from $58 while maintaining Buy. Article: Liquidia extends gains as Raymond James upgrades on Yutrepia launch
• Neutral Sentiment: Analyst views remain divided: BTIG reiterated Buy, while Wells Fargo maintained Hold, despite lifting its price target to $40 from $33. Article: BTIG Reaffirms Their Buy Rating on Liquidia Technologies Article: Wells Fargo Sticks to Its Hold Rating for Liquidia Technologies

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.